Anyone affected by internal bleeding after taking Pradaxa is encouraged visit the DrugRisk resource center or speak with a lawyer about their legal options.
Chicago, IL (PRWEB) June 10, 2013
The prescription drug safety advocates at DrugRisk.com are alerting patients taking the blood thinner Pradaxa of updated information on the site. As the number of injury claims grows*****, a new study warns that patients may not be taking the drug correctly and there may be an added risk when switching from other blood thinners*.
DrugRisk was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Pradaxa was launched in 2010 to prevent strokes in patients with atrial fibrillation. Experts disagree, however, about whether it carries higher risks for internal bleeding.
The FDA recently advised that Pradaxa is no more dangerous than traditional blood thinner warfarin**. However, DrugRisk contains information from the Institute for Safe Medication Practices, who warned that patients suffering Pradaxa bleeding are nearly 5 times as likely to die than those with bleeding from Coumadin or warfarin. They also named anticoagulants like Pradaxa among the most dangerous drugs available***.
The resource center also contains research from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected****.
Now, DrugRisk is announcing a new study from Denmark published this month which shows many patients may be using Pradaxa improperly, and the risks of internal bleeding are heightened when switching from other blood thinners*.
Due to the number of patients who have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
DrugRisk notes a new report by the Judicial Panel on Multidistrict Litigation showing the number of cases has grown in recent months from 260 on March 5th to 663 as of May 15, 2013*****.
Anyone affected by internal bleeding after taking Pradaxa is encouraged visit the DrugRisk resource center or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
*British Medical Journal, 5/3/13; bmjopen.bmj.com/content/3/5/e002758.long
**FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834
*****Judicial Panel on MultiDistrict Litigation 5/15/13; jpml.uscourts.gov/sites/jpml/files/Pending%20MDL%20Dockets_By%20District_May-14-2013.pdf